Skip to Content

Gallium ga 68 dotatate Pregnancy and Breastfeeding Warnings

Gallium ga 68 dotatate is also known as: Netspot

Gallium ga 68 dotatate Pregnancy Warnings

There are no controlled data in human pregnancy. The estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively.

Safety has not been established during pregnancy.

Risk Summary:
-There are no studies in pregnant women to inform any drug-associated risks; however, all radiopharmaceuticals, including this drug have the potential to cause fetal harm.

See references

Gallium ga 68 dotatate Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comment: Interrupt breastfeeding and pump and discard breast milk for 12 hours after administration of this drug to minimize radiation exposure to a breastfed infant.

See references

References for pregnancy information

  1. "Product Information. Netspot (dotatate)." Advanced Accelerator Applications, New York, NY.

References for breastfeeding information

  1. "Product Information. Netspot (dotatate)." Advanced Accelerator Applications, New York, NY.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide